www.turner-white.com Oncology Volume 10, Part 6 15
diovascular side effects of diethylstilbestrol, cyproterone
acetate, medroxyprogesterone acetate and estramustine
phosphate used in the treatment of advanced prostatic
cancer: results from the European Organization for Research on Treatment of Cancer trials 30761 and 30762. J
Urol 1986;135:303–7.
21. Parys BT, Hamid S, Thomson RG. Severe hepatocellular
dysfunction following cyproterone acetate therapy. Br J
Urol 1991;67:312–3.
22. Brufsky A, Fontaine-Rothe P, Berlane K, et al. Finasteride
and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology
1997; 490:913–20.
23. Schröder FH, Collette L, de Reijke TM, et al. Prostate
cancer treated by antiandrogens: is sexual function preserved?. Br J Cancer 2000;82:283–90.
24. Lund F, Rasmussen F. Flutamide versus stilbestrol in the
management of advance prostatic cancer: a controlled
prospective study. Br J Urol 1988;61:140– 2.
25. Han M, Nelson JB. Non-steroidal anti-androgens in prostate cancer: current treatment practice. Exp Opin Pharma-cother 2000;1:443–9.
26. Wysowski DK, Freiman JP, Tourtelot JB, et al. Fatal and
nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993;118:860– 4.
27. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic
review and meta-analysis of monotherapy compared with
combined androgen blockade for patients with advanced
prostate carcinoma. Cancer 2002;95:361–6.
28. Kelly WK, Scher HI. Prostate specific antigen decline after
antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993;149:607–9.
29. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients
with advanced prostate cancer. Cancer 1995;76:1428–34.
30. Taplin M-E, Bubley GJ, Shuster TD, et al. Mutation of the
androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393–8.
31. Suzuki H, Akakura K, Komiya A, et al. Codon 877 mutation
in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996;29:153–8.
32. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow up
of Radiation Therapy Oncology Group Protocol 92-02: a
phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol
2008;26:2497–504.
33. D’Amico AV, Chen MH, Renshaw AA, et al. Androgen
suppression and radiation vs. radiation alone for prostate
cancer. JAMA 2008;299:289–95.
34. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of
androgen suppression in the treatment of prostate cancer.
N Engl J Med 2009;360:2516–27.
35. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781–8.
36. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical
prostatectomy and pelvic lymphadenectomy in men with
node positive prostate cancer: results at 10 years of EST
3886. J Urol 2003;169:396, A1480.
37. Moul JW, WU H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol
2008;179( 5 Suppl):S53–9.
38. Ryan CJ, Small EJ. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J
Clin Oncol 2005;23:8225–31.
39. Medical Research Council Prostate Cancer Working Party
Investigators Group. Immediate versus deferred treatment
for advanced prostatic cancer: initial results of the Medical
Research Council Trial. Br J Urol 1997;79:235–46.
40. Kirk D. Timing and choice of androgen ablation. Prostate
Can Prostatic Dis 2004;7:217–22.
41. Akakura K, Bruchovsky N, Goldenberg SL, et al. Effects
of intermittent androgen suppression on androgen-de-pendent tumors: apoptosis and serum prostate-specific
antigen. Cancer 1993;71:2782–90.
42. Sato N, Gleave M, Bruchovsky N, et al. Effects of intermittent androgen suppression delays progression to
androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid
Biochem Mol Biol 1996;58:139–46.
43. Mottet N, Damme JV, Loulidi S, et al. Intermittent hormonal
therapy in the treatment of metastatic prostate cancer: a
randomized trial. BJU Int 2012;110:1262–9.
44. Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent
androgen deprivation for locally advanced and metastatic
prostate cancer: results from a randomized phase III study
of the South European Uroncological Group. Eur Urol
2009;55:1269–77.
45. Crook JM, O’Callaghan CJ, Duncan G, et al. N Engl J Med
20126;367:895–903.
46. Hussain M, Tangen CM, Berry DL, et al. N Engl J Med
2013;368:1314–25.
47. Smith M, Finkelstein JS, McGover FJ, et al. Changes in
body composition during androgen deprivation therapy for
prostate cancer. J Clin Endocrin Metab 2002;87:599–603.
48. Moyad MA. Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer
